↓ Skip to main content

Wiley Online Library

Episodic and Chronic Migraine Headache: Breaking Down Barriers to Optimal Treatment and Prevention

Overview of attention for article published in Headache: The Journal of Head & Face Pain, February 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (88th percentile)
  • Good Attention Score compared to outputs of the same age and source (73rd percentile)

Mentioned by

blogs
1 blog
twitter
6 tweeters
facebook
1 Facebook page
googleplus
1 Google+ user

Citations

dimensions_citation
70 Dimensions

Readers on

mendeley
107 Mendeley
Title
Episodic and Chronic Migraine Headache: Breaking Down Barriers to Optimal Treatment and Prevention
Published in
Headache: The Journal of Head & Face Pain, February 2015
DOI 10.1111/head.12505_2
Pubmed ID
Authors

Richard B. Lipton, Stephen D. Silberstein

Abstract

Migraine is a common disabling primary headache disorder that affects an estimated 36 million Americans. Migraine headaches often occur over many years or over an individual's lifetime. By definition, episodic migraine is characterized by headaches that occur on fewer than 15 days per month. According to the recent International Classification of Headache Disorders (third revision) beta diagnostic criteria, chronic migraine is defined as "headaches on at least 15 days per month for at least 3 months, with the features of migraine on at least 8 days per month." However, diagnostic criteria distinguishing episodic from chronic migraine continue to evolve. Persons with episodic migraine can remit, not change, or progress to high-frequency episodic or chronic migraine over time. Chronic migraine is associated with a substantially greater personal and societal burden, more frequent comorbidities, and possibly with persistent and progressive brain abnormalities. Many patients are poorly responsive to, or noncompliant with, conventional preventive therapies. The primary goals of migraine treatment include relieving pain, restoring function, and reducing headache frequency; an additional goal may be preventing progression to chronic migraine. Although all migraineurs require abortive treatment, and all patients with chronic migraine require preventive treatment, there are no definitive guidelines delineating which persons with episodic migraine would benefit from preventive therapy. Five US Food and Drug Association strategies are approved for preventing episodic migraine, but only injections with onabotulinumtoxinA are approved for preventing chronic migraine. Identifying persons who require migraine prophylaxis and selecting and initiating the most appropriate treatment strategy may prevent progression from episodic to chronic migraine and alleviate the pain and suffering associated with frequent migraine.

Twitter Demographics

The data shown below were collected from the profiles of 6 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 107 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Germany 1 <1%
South Africa 1 <1%
Brazil 1 <1%
United States 1 <1%
Unknown 103 96%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 19 18%
Student > Master 17 16%
Other 13 12%
Unspecified 11 10%
Student > Doctoral Student 11 10%
Other 36 34%
Readers by discipline Count As %
Medicine and Dentistry 46 43%
Unspecified 19 18%
Agricultural and Biological Sciences 11 10%
Biochemistry, Genetics and Molecular Biology 6 6%
Nursing and Health Professions 5 5%
Other 20 19%

Attention Score in Context

This research output has an Altmetric Attention Score of 12. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 January 2016.
All research outputs
#1,124,127
of 12,353,915 outputs
Outputs from Headache: The Journal of Head & Face Pain
#287
of 2,323 outputs
Outputs of similar age
#30,115
of 267,325 outputs
Outputs of similar age from Headache: The Journal of Head & Face Pain
#18
of 63 outputs
Altmetric has tracked 12,353,915 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,323 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.3. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 267,325 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 63 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.